{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:57:28Z","timestamp":1773154648275,"version":"3.50.1"},"reference-count":63,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T00:00:00Z","timestamp":1152662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in hemophiliacs who received nonvirucidally treated large\u2010pool clotting factor concentrates before 1986. In fact, although many hemophiliacs infected with HCV have a slow progression of liver disease, in a minority of them hepatitis evolves toward end\u2010stage liver disease and hepatocarcinoma. Moreover, a significant percentage of HCV\u2010infected hemophiliacs were also coinfected with human immunodeficiency virus (HIV), which can accelerate the progression of liver disease. Thus, the aim of anti\u2010HCV therapy is to interrupt the chronic infection in order to prevent the progression of hepatitis to cirrhosis, liver decompensation, cancer and, ultimately, death. In this review we present the literature data on anti\u2010HCV treatment in hemophiliacs. Combination therapy with interferon (IFN) and ribavirin has improved the poor results obtained with IFN monotherapy and has become the standard treatment of chronic hepatitis C. Given the positive results obtained with pegylated interferon plus ribavirin in nonhemophiliacs, ongoing trials are evaluating this promising therapy in HCV\u2010chronically infected hemophilic patients; preliminary results show a sustained response rate similar to that in patients without coagulopathy. Finally, based on the encouraging results in coinfected nonhemophiliacs, anti\u2010HCV treatment should also be considered for those HIV\u2010positive hemophiliacs in whom anti\u2010retroviral treatment has stabilized the HIV infection. Am. J. Hematol., 2006. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20701","type":"journal-article","created":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T22:11:57Z","timestamp":1152742317000},"page":"696-702","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of hepatitis C in hemophiliacs"],"prefix":"10.1002","volume":"81","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00391-5"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00058.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1836"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91124-S"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.2.412.412"},{"key":"e_1_2_1_7_2","first-page":"542","article-title":"Update on chronic hepatitis C in hemophiliacs","volume":"87","author":"Franchini M","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.02343.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08312.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.6.845"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80029-4"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1160\/TH04-08-0510","article-title":"Hepatitis C in haemophiliacs","volume":"92","author":"Franchini M","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00398.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440577.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/blood.V78.7.1672.1672","article-title":"A randomized controlled trial of recombinant interferon\u2010\u03b1 in chronic hepatitis C in hemophiliacs","volume":"78","author":"Makris M","year":"1991","journal-title":"Blood"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00332.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00040.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V87.5.1704.1704","article-title":"Interferon treatment for chronic hepatitis C infection in hemophiliacs\u2014influence of virus load, genotype and liver pathology on response","volume":"87","author":"Hanley JP","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04835.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00141.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200107000-00015"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02347513"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.2_Suppl.S124"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00039.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01355.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V91.2.727","article-title":"High\u2010dose and long\u2010term therapy of \u03b1\u2010interferon in hemophilic patients with chronic C virus hepatitis","volume":"9","author":"Pinilla J","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00444.x"},{"key":"e_1_2_1_28_2","first-page":"3529","article-title":"A multicenter controlled, randomized, open trial of interferon \u03b12b treatment of anti\u2010human immunodeficiency virus\u2010negative hemophilic patients with chronic hepatitis C","volume":"89","author":"Rumi MG","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392102"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06088-1"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00527.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01872.x"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1055\/s-0037-1613924","article-title":"Treatment with interferon plus ribavirin in anti\u2010HIV negative patients with congenital coagulation disorders and chronic hepatitis C","volume":"83","author":"Sauleda S","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02700.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00629.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35529"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03154.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1089"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00682.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00843.x"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.0562c.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432302"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"issue":"1","key":"e_1_2_1_48_2","first-page":"48","article-title":"Sustained suppression of hepatitis C by pegylated interferon (pegIFN) and ribavirin in hemophilic patients","volume":"10","author":"Mancuso ME","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_1_49_2","first-page":"35","article-title":"Treatment of chronic hepatitis C in hemophilic patients","volume":"48","author":"Husa P","year":"2004","journal-title":"Acta Virol"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00828.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904010-00002"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00491.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200401020-00001"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/344755"},{"issue":"1","key":"e_1_2_1_55_2","first-page":"50","article-title":"Treatment with peg\u2010interferon \u03b1\u20102b and ribavirin in patients with congenital hemorrhagic disorders and HCV infection","volume":"10","author":"Theodossiades G","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603283341302"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70454-3"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198505023121812"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.6.1721.1721"},{"key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V93.3.1113","article-title":"Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome","volume":"93","author":"Ragni MV","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00306.x"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.5.744"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03528.x"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3310"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20701","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:59:16Z","timestamp":1696003156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,12]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1002\/ajh.20701"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20701","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,12]]}}}